奈达铂化疗联合同期放疗治疗中晚期宫颈癌临床疗效分析

摘要

Objective:To explore the clinical effects of advanced cervical carcinoma by nedaplatin combine with concurrent chemoradiotherapy.Method: 135 cases of patients with advanced cervical carcinoma were randomly divided into group A, group B and group C,45 cases in each group. The group A was treated by nedaplatin combine with concurrent chemoradiotherapy, the group B was treated by cisplatin combine with concurrent chemoradiotherapy, the group C was treated by radiation. The clinical effects and adverse reactions were compared.Result: There was no significant difference on the total effective rate for group A and group B(P>0.05). The total effective rate for group A and group B were higher than group C, the difference was statistically significant(P<0.05). The rate of adverse reactions of I~IV for the group A were lower than the group B,the difference was statistically significant (P<0.05). The rate of adverse reactions of I for the group A were lower than the group B,the difference was statistically significant (P<0.05).Conclusion: The clinical effects of advanced cervical carcinoma by nedaplatin combine with concurrent chemoradiotherapy is good, it has high clinical effects, with low adverse reactions. It is worthy of clinical promotion.%目的：探讨奈达铂化疗联合同期放疗治疗中晚期宫颈癌临床疗效。方法：选取2012年1月-2014年6月本院收治的宫颈癌患者135例作为研究对象。按照随机数字表法将患者均分为A组、B组和C组，每组45例。A组采取奈达铂化疗联合放疗治疗，B组采取顺铂化疗联合放疗治疗，C组采取单纯放疗治疗。观察三组患者临床疗效及不良反应发生情况。结果：A组与B组临床总有效率比较，差异无统计学意义（P>0.05）；A组、B组总有效率显著高于C组，差异具有统计学意义（P<0.05）。A组和B组I~IV度不良反应发生率比较， A组显著低于B组，差异具有统计学意义（P<0.05）。A组I度不良反应发生率显著低于B组，差异具有统计学意义（P<0.05）。结论：奈达铂化疗联合同期放疗治疗中晚期宫颈癌临床疗效佳，其临床疗效与顺铂化疗联合放疗临床疗效相当，且不良反应发生率较低，值得临床推广。